Dr Annamaria Iakovou outlines the importance of recognizing EDS in people who are living with OSA or narcolepsy, and provides practical guidance on how to meaningfully evaluate and determine the primary underlying cause.1/3 Next Interview
Prof. Helene A Emsellem outlines current treatment approaches and explores how the management of EDS may be optimized for people living with OSA or narcolepsy.2/3 Next Interview
Prof. Gert Jan Lammers explores the emerging treatment landscape, appraising the latest clinical evidence for new and emerging agents, and contextualizing the potential implications for the future management of EDS.3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, leading sleep medicine physicians explore strategies for the optimal management of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) or narcolepsy and share insights and potential implications for clinical practice.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of neurology and respiratory physicians, including sleep specialists, neurologists and psychiatrists, as well as primary care physicians involved in the management of excessive daytime sleepiness.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Annamaria Iakovou has no interests/relationships or affiliations to disclose in relation to this activity.
Prof. Helene A Emsellem discloses Advisory board or panel fees from Harmony Biosciences, Jazz Pharmaceuticals and Takeda. Consultant fees from Respironics and Vanda Pharmaceuticals. Grants/research support from Apnimed, Avadel Pharmaceuticals, Axsome Therapeutics, Harmony Biosciences, Idorsia, Imbrium Therapeutics, Jazz Pharmaceuticals, Merck, Respironics, Suven Life Sciences and Takeda. Speaker’s bureau fees from Jazz Pharmaceuticals.
Prof. Gert Jan Lammers discloses Consultancy fees from Jazz Pharmaceuticals. Grants/research support from Bioprojet, Jazz Pharmaceuticals and UCB.
Karim H Hanna, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Christina Mackins-Crabtree, PhD, CMPP has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 02 December 2021. Date credits expire: 02 December 2022.
If you have any questions regarding credit please contact firstname.lastname@example.org
After watching this activity, participants should be better able to:
- Distinguish EDS from fatigue/tiredness, improving the ability to differentially diagnose OSA and narcolepsy
- Apply non-pharmacological and pharmacological management strategies for EDS in OSA or narcolepsy
- Interpret key efficacy and safety data on emerging therapies for the management of EDS in OSA and narcolepsy